[EN] HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LA MODULATION DE NR2F6
申请人:TES PHARMA S R L
公开号:WO2021170658A1
公开(公告)日:2021-09-02
The present disclosure relates to compounds capable of modulating the activity of NR2F6. The compounds of the disclosure may be used in methods for the prevention and/or the treatment of diseases and disorders associated with modulating NR2F6 activity.
A library of 26 novel carboxamides deriving from natural fislatifolic acid has been prepared. The synthetic strategy involved a bio-inspired Diels-Alder cycloaddition, followed by functionalisations of the carbonyl moiety. All the compounds were evaluated on Bcl-xL, Mcl-1 and Bcl-2 proteins. In this series of cyclohexenyl chalcone analogues, six compounds behaved as dual Bcl-xL/Mcl-1 inhibitors in
<i>N</i>-Acylation of Oxazolidinones via Aerobic Oxidative NHC Catalysis
作者:Linda Ta、Anton Axelsson、Henrik Sundén
DOI:10.1021/acs.joc.8b01723
日期:2018.10.5
synthetically useful oxazolidinones with aldehydes using aerobicoxidative NHC catalysis is reported. The reaction offers a broad scope of functionalized oxazolidinones in good to excellent yields. Careful choice of electron transfer mediators proved pivotal to achieve efficient aerobic N-acylation, which has previously proven difficult using NHC catalysis. The methodology allows a mild entry to acylated oxazolidinones
A Practical Method for<i>N</i>-Acylation of Bornane-2,10-sultam and 2-Oxazolidinones
作者:Catriona Thom、Philip Kocieński
DOI:10.1055/s-1992-26169
日期:——
The N-trimethylsilyl derivatives of (+)-bornane-2,10-sultam (10,10-dimethyl-5-thia-4-azatricyclo[5.2.1.03,7]decane 5,5-dioxide) and (R)-4-benzyl-2-oxazolidinone and 4-methyl-5-phenyl-2-oxazo-lidinone react with acid chlorides in refluxing benzene in the presence of copper(II) chloride to give the corresponding N-acyl derivatives in good yield.
Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.